Proteasome inhibition in multiple myeloma: Therapeutic implication

Annual Review of Pharmacology and Toxicology

Volumn 45, Issue , 2005, Pages 465-476

  Chauhan, Dharminder ^a   Hideshima, Teru ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Drug resistance; Growth; Plasma call neoplasm; Proteasomes; Survival

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 9; DEXAMETHASONE; MELPHALAN; PROTEASOME INHIBITOR; THALIDOMIDE;

ANIMAL CELL; APOPTOSIS; BONE MARROW CELL; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; RELAPSE; REVIEW; RNA TRANSLATION; STROMA CELL; TARGET CELL;

ANIMALS; HUMANS; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

ANIMALIA;

EID: 13844320703     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.45.120403.100037     Document Type: Review

References (67)

1. Anderson KC. 2004. Bortezomib therapy for myeloma. Curr. Hematol. Rep. 3:65
2. Anderson KC. 2004. Plasma cell tumors. In Cancer Medicine, ed. JF Holland, E Frei III, RC Bast, DW Kufe, DL Norton, RR Weichselbaum. Baltimore: Williams and Wilkins. In press
3. Wyllie A. 1980. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555-56
4. Reed JC. 1999. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17:2941-53
5. Chauhan D, Hideshima T, Anderson KC. 2003. Apoptotic signaling in multiple myeloma: therapeutic implications. Int. J. Hematol. 78:114-20
6. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, et al. 2001. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:3071-76
7. Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, et al. 2003. Bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 103(8):3158-66
8. Anderson KC. 2003. Moving disease biology from the lab to the clinic. Cancer 97:796-801
9. Nefedova Y, Landowski TH, Dalton WS. 2003. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17:1175-82
10. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. 1995. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2:493-506
11. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. 1999. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93:1658-67
12. Schenkein D. 2002. Proteasome inhibitors in the treatment of B-cell malignancies. Clin. Lymphoma 3:49-55
13. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, et al. 1999. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93:3064-73
14. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, et al. 2001. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98:428-35
15. Oikawa T, Sasaki T, Nakamura M, Shimamura M, Tanahashi N, et al. 1998. The proteasome is involved in angiogenesis. Biochem. Biophys. Res. 246:243-48
16. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, et al. 2001. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7:1419-28
17. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, et al. 2002. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA 99:14374-79
18. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, et al. 2003. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377-80
19. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, et al. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348:2609-17
20. Karin M, Ben-Neriah Y. 2000. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18:621-63
21. Lee JC, Peter ME. 2003. Regulation of apoptosis by ubiquitination. Immunol. Rev. 193:39-47
22. Brooks CL, Gu W. 2003. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15:164-71
23. Almond JB, Cohen GM. 2002. The proteasome: a novel target for cancer chemotherapy. Leukemia 16:433-43
24. Elliott PJ, Ross JS. 2001. The proteasome: a new target for novel drug therapies. Am. J. Clin. Pathol. 116:637-46
25. Yew PR, Kirschner MW. 1997. Proteolysis and DNA replication: the CDC34 requirement in the Xenopus egg cell cycle. Science 277:1672-76
26. Verma R, Feldman RM, Deshaies RJ. 1997. SIC1 is ubiquitinated in vitro by a pathway that requires CDC4, CDC34, and cyclin/CDK activities. Mol. Biol. Cell. 8:1427-37
27. Goebl MG, Yochem J, Jentsch S, McGrath JP, Varshavsky A, Byers B. 1988. The yeast cell cycle gene CDC34 encodes a ubiquitin-conjugating enzyme. Science 241:1331-35
28. Adams J. 2004. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4:349-60
29. Goldberg AL, Rock K. 2002. Not just research tools-proteasome inhibitors offer therapeutic promise. Nat. Med. 8:338-40
30. Pickart CM. 2004. Back to the future with ubiquitin. Cell 116:181-90
31. Ciechanover A, Schwartz AL. 1998. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc. Natl. Acad. Sci. USA 95:2727-30
32. Ciechanover A. 2003. The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. Biochem. Soc. Trans. 31:474-81
33. Elliott PJ, Pien CS, McCormack ID, Chapman ID, Adams J. 1999.Proteasome inhibition: a novel mechanism to combat asthma. J. Allergy Clin. Immunol. 104:1-7
34. Lupas A, Koster AJ, Baumeister W. 1993. Structural features of 26S and 20S proteasomes. Enzyme Protein 47:252-73
35. Eytan E, Ganoth D, Armon T, Hershko A. 1989. ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin. Proc. Natl. Acad. Sci. USA 86:7751-55
36. Masdehors P, Omura S, Merle-Beral H, Mentz F, Cosset J-M, et al. 1999. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br. J. Haematol. 105:752-57
37. Drexler HC, Risau W, Konerding MA. 2000. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J. 14:65-77
38. Kudo Y, Takata T, Ogawa I, Kaneda T, Sato S, et al. 2000. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin. Cancer Res. 6:916-23
39. Bogner C, Schneller F, Hipp S, Ringshausen I, Peschel C, Decker T. 2003. Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways. Exp. Hematol. 31:218-25
40. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, et al. 2002. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. USA 99:16220-25
41. Stancovski I, Baltimore D. 1997. NF-κB activation: the IκB kinase revealed? Cell 91:299-302
42. Haefner B. 2002. NF-kappa B: arresting a major culprit in cancer. Drug Discov. Today 7:653-63
43. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. 1998. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 91:4624-31
44. Alkalay I, Yaron A, Hatzubai A, Jung S, Avraham A, et al. 1995. In vivo stimulation of I kappa B phosphorylation is not sufficient to activate NF-kappa B. Mol. Cell Biol. 15:1294-301
45. Karin M, Yamamoto Y, Wang QM. 2004. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3:17-26
46. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, et al. 1996. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87:1104-12
47. Feinman R, Koury J, Thames M, Barlogie B, Epstein J. 1999. Role of NF-kB in the rescue of multiple myeloma cells from glucocorticoids-induced apoptosis by Bcl-2. Blood 93:3044-52
48. Ogawa M, Nishiura T, Oritani K, Yoshida H, Yoshimura M, et al. 2000. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res. 60:4262-69
49. Chauhan D, Anderson KC. 2003. Mechanisms of cell death and survival in multiple myeloma (MM): therapeutic implications. Apoptosis 8:337-43
50. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, et al. 2003. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9:1136-44
51. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, et al. 2002. NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. 28:28
52. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, et al. 2002. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99:4079-86
53. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, et al. 2003. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 63:6174-77
54. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, et al. 2003. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J. Biol. Chem. 278:17593-96
55. Chauhan D, Guilan L, Sattler M, Hideshima T, Podar K, et al. 2003. Superoxide-dependent and independent mitochondrial signaling during apoptosis in multiple myeloma (MM) cells. Oncogene 22:6296-300
56. Hideshima T, Anderson KC. 2002. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer 2:927-37
57. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, et al. 2003. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530-34
58. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, et al. 2003. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood 102:3379-86
59. Concannon CG, German AM, Samali A. 2003. On the role of Hsp27 in regulating apoptosis. Apoptosis 8:61-70
60. Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, et al. 2000. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat. Cell Biol. 2:645-52
61. Cory S, Adams JM. 2002. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2:647-56
62. Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, et al. 2004. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 103:3158-66
63. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, et al. 2001. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 82:110-22
64. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, et al. 2001. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61:3535-40
65. Adams J. 2002. Development of the proteasome inhibitor PS-341. Oncologist 7:9-16
66. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, et al. 2002. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20:4420-27
67. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, et al. 2002. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8:2505-11